US Pharmaceutical Tariff Shock

The Trump administration’s 100% tariff on patented drug imports threatens Australian pharmaceutical exports worth roughly US$1.32 billion to the US. Although CSL may secure carve-outs, the measure raises trade uncertainty, pressures investment decisions, and may accelerate production shifts abroad.

US Tariffs Reshape Export Flows

Exports to the United States fell 9.1% in March and 18.7% in Q1 after 2025 tariff hikes. With 22% of Brazilian exports still affected, manufacturers and exporters face margin pressure, market diversification costs and weaker North American sales visibility.

Semiconductor Export Control Escalation

Washington is tightening technology restrictions on China through the proposed MATCH Act, targeting DUV lithography, servicing, and allied suppliers. The measures could reshape semiconductor capital equipment flows, raise compliance burdens, and reinforce geographic fragmentation across advanced electronics supply chains.

Regional Conflict Supply Exposure

Conflict spillovers from Iran and wider Middle East instability threaten logistics, tourism, export demand and supplier continuity. Turkish officials estimate the shock could widen the current account deficit by around 1 percentage point and shave about 0.5 points off growth.

War-Driven Oil Price Leverage

Conflict has increased Iran’s oil revenues even as wider Gulf exporters face disruption. Reports indicate daily revenues nearly doubled as Brent-linked prices surged and discounts to Chinese buyers narrowed from $18-24 per barrel to about $7-12, amplifying energy market volatility for importers.

Critical Minerals Alliance Expansion

Australia is rapidly deepening critical-minerals partnerships with the US, EU, Japan and France, supported by an A$1.2 billion strategic reserve, 49 mining projects and 29 processing ventures. This could reshape investment flows, export mix, and allied supply-chain positioning.